Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NOTCH3 regulates stem-to–mural cell differentiation in infantile hemangioma
Andrew K. Edwards, Kyle Glithero, Peter Grzesik, Alison A. Kitajewski, Naikhoba C.O. Munabi, Krista Hardy, Qian Kun Tan, Michael Schonning, Thaned Kangsamaksin, Jan K. Kitajewski, Carrie J. Shawber, June K. Wu
Andrew K. Edwards, Kyle Glithero, Peter Grzesik, Alison A. Kitajewski, Naikhoba C.O. Munabi, Krista Hardy, Qian Kun Tan, Michael Schonning, Thaned Kangsamaksin, Jan K. Kitajewski, Carrie J. Shawber, June K. Wu
View: Text | PDF
Research Article Vascular biology

NOTCH3 regulates stem-to–mural cell differentiation in infantile hemangioma

  • Text
  • PDF
Abstract

Infantile hemangioma (IH) is a vascular tumor that begins with rapid vascular proliferation shortly after birth, followed by vascular involution in early childhood. We have found that NOTCH3, a critical regulator of mural cell differentiation and maturation, is expressed in hemangioma stem cells (HemSCs), suggesting that NOTCH3 may function in HemSC-to–mural cell differentiation and pathological vessel stabilization. Here, we demonstrate that NOTCH3 is expressed in NG2+PDGFRβ+ perivascular HemSCs and CD31+GLUT1+ hemangioma endothelial cells (HemECs) in proliferating IHs and becomes mostly restricted to the αSMA+NG2loPDGFRβlo mural cells in involuting IHs. NOTCH3 knockdown in HemSCs inhibited in vitro mural cell differentiation and perturbed αSMA expression. In a mouse model of IH, NOTCH3 knockdown or systemic expression of the NOTCH3 inhibitor, NOTCH3 Decoy, significantly decreased IH blood flow, vessel caliber, and αSMA+ perivascular cell coverage. Thus, NOTCH3 is necessary for HemSC-to–mural cell differentiation, and adequate perivascular cell coverage of IH vessels is required for IH vessel stability.

Authors

Andrew K. Edwards, Kyle Glithero, Peter Grzesik, Alison A. Kitajewski, Naikhoba C.O. Munabi, Krista Hardy, Qian Kun Tan, Michael Schonning, Thaned Kangsamaksin, Jan K. Kitajewski, Carrie J. Shawber, June K. Wu

×

Figure 1

NOTCH3 is expressed in perivascular and lumenal cells in IHs.

Options: View larger image (or click on image) Download as PowerPoint
NOTCH3 is expressed in perivascular and lumenal cells in IHs.
Serial sec...
Serial sections of proliferating and involuting infantile hemangioma (IH) specimens were stained. (A) GLUT1 and CD31 costaining. White arrowheads mark GLUT1+CD31+ cells. Proliferating IH n = 2, involuting IH n = 3. (B) GLUT1 and αSMA costaining. Yellow arrowheads mark αSMA+GLUT1– perivascular cells. Proliferating IH n = 2, involuting IH n = 7. (C) NOTCH3 and CD31 costaining. White arrowheads mark NOTCH3+CD31+ cells. Yellow arrowheads mark NOTCH3+CD31– cells. Proliferating IH n = 4, involuting IH n = 5. (D) NOTCH3 and αSMA costaining. White arrowheads mark NOTCH3+αSMA+ perivascular cells. Yellow arrowheads mark NOTCH3+αSMA– lumenal cells. Proliferating IH n = 5, involuting IH n = 8. Scale bars: 50 μm. The total number of IH specimens assessed for each antigen is presented in Supplemental Table 3. αSMA, α smooth muscle actin; GLUT1, glucose transporter 1.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts